Alys Pharmaceuticals receives IND clearance for Phase 2a trial of first genetic medicine program in dermatology
- ALY-101 is an intradermal injectable JAK1 siRNA-lipid conjugate for the treatment of Alopecia Areata
- Significant progress made in advancing the Alys pipeline following $100m seed financing from Medicxi
Boston, Massachusetts and Lausanne, Switzerland, 4th February 2025 – Alys Pharmaceuticals, Inc. (“Alys”), an immune-dermatology focused company, today announces that the U.S. Food and Drug Administration (FDA) and Health Canada have cleared the Investigational New Drug (IND) / Clinical Trial Application (CTA) for the study of ALY-101 in patients suffering from Alopecia Areata (AA).